EP1401427A4 - Non-peptide gnrh agents, pharmaceutical compositions and methods for their uses, and processes for preparing them - Google Patents

Non-peptide gnrh agents, pharmaceutical compositions and methods for their uses, and processes for preparing them

Info

Publication number
EP1401427A4
EP1401427A4 EP02739712A EP02739712A EP1401427A4 EP 1401427 A4 EP1401427 A4 EP 1401427A4 EP 02739712 A EP02739712 A EP 02739712A EP 02739712 A EP02739712 A EP 02739712A EP 1401427 A4 EP1401427 A4 EP 1401427A4
Authority
EP
European Patent Office
Prior art keywords
preparing
processes
methods
pharmaceutical compositions
peptide gnrh
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP02739712A
Other languages
German (de)
French (fr)
Other versions
EP1401427A2 (en
Inventor
Eric T Sun
Mark B Anderson
Kenna Lynn Anderes
Lance Christopher Christie
Quyen-Quyen Thuy Do
Jun Feng
Thomas Goetzen
Yufeng Hong
Eugenia Anatolievna Kraynov
Haitao Li
David Robert Luthin
Genevieve D Paderes
Ved P Pathak
Ranjan Jagath Rajapakse
Scott Shackelford
Eileen Valenzuela Tompkins
Larry Kenneth Truesdale
Haresh VAZIR
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Agouron Pharmaceuticals LLC
Original Assignee
Agouron Pharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agouron Pharmaceuticals LLC filed Critical Agouron Pharmaceuticals LLC
Publication of EP1401427A2 publication Critical patent/EP1401427A2/en
Publication of EP1401427A4 publication Critical patent/EP1401427A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Virology (AREA)
  • Reproductive Health (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Furan Compounds (AREA)
EP02739712A 2001-06-06 2002-06-05 Non-peptide gnrh agents, pharmaceutical compositions and methods for their uses, and processes for preparing them Withdrawn EP1401427A4 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US29581201P 2001-06-06 2001-06-06
US295812P 2001-06-06
US30186801P 2001-06-29 2001-06-29
US301868P 2001-06-29
PCT/US2002/017846 WO2002098363A2 (en) 2001-06-06 2002-06-05 NON-PEPTIDE GnRH AGENTS, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR THEIR USES, AND PROCESSES FOR PREPARING THEM

Publications (2)

Publication Number Publication Date
EP1401427A2 EP1401427A2 (en) 2004-03-31
EP1401427A4 true EP1401427A4 (en) 2004-12-01

Family

ID=26969346

Family Applications (1)

Application Number Title Priority Date Filing Date
EP02739712A Withdrawn EP1401427A4 (en) 2001-06-06 2002-06-05 Non-peptide gnrh agents, pharmaceutical compositions and methods for their uses, and processes for preparing them

Country Status (7)

Country Link
EP (1) EP1401427A4 (en)
JP (1) JP2005501006A (en)
AU (1) AU2002312348A1 (en)
BR (1) BR0210191A (en)
CA (1) CA2449843A1 (en)
MX (1) MXPA03011002A (en)
WO (1) WO2002098363A2 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0130341D0 (en) 2001-12-19 2002-02-06 Smithkline Beecham Plc Compounds
US7205307B2 (en) * 2002-02-14 2007-04-17 Icagen, Inc. Pyrimidines as novel openers of potassium ion channels
JP2005538064A (en) 2002-06-13 2005-12-15 ファイザー・インク Non-peptide GnRH agents, pharmaceutical compositions and methods for their use
US7332521B2 (en) * 2003-09-25 2008-02-19 Wyeth Substituted indoles
EP1541549A1 (en) 2003-12-12 2005-06-15 Exonhit Therapeutics S.A. Tricyclic hydroxamate and benzaminde derivatives, compositions and methods
KR101433629B1 (en) * 2006-09-11 2014-08-27 쿠리스 인코퍼레이션 Tyrosine kinase inhibitors containing a zinc binding moiety
UA103319C2 (en) 2008-05-06 2013-10-10 Глаксосмитклайн Ллк Thiazole- and oxazole-benzene sulfonamide compounds
CN102329234B (en) * 2011-06-24 2013-11-06 灌南伊斯特化工有限公司 Production process of m-nitrobenzaldehyde
EP2712862A1 (en) * 2012-09-28 2014-04-02 Splicos New anti-invasive compounds
EP2986603A1 (en) * 2013-04-19 2016-02-24 Oslo Universitetssykehus HF Radiolabeled gnrh antagonists as pet imaging agents
CN108905641B (en) * 2018-08-01 2020-04-28 湖南七纬科技有限公司 Nanofiltration membrane and preparation method thereof
CN114105775A (en) * 2021-11-30 2022-03-01 武汉工程大学 Preparation method of substituted iodobenzene with terminal double bond

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999044987A1 (en) * 1998-03-05 1999-09-10 Agouron Pharmaceuticals, Inc. NON-PEPTIDE GnRH AGENTS
WO2000020358A2 (en) * 1998-08-20 2000-04-13 Agouron Pharmaceuticals, Inc. NON-PEPTIDE GnRH AGENTS, METHODS AND INTERMEDIATES FOR THEIR PREPARATION

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU751139B2 (en) * 1997-10-13 2002-08-08 Astellas Pharma Inc. Amide derivative

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999044987A1 (en) * 1998-03-05 1999-09-10 Agouron Pharmaceuticals, Inc. NON-PEPTIDE GnRH AGENTS
WO2000020358A2 (en) * 1998-08-20 2000-04-13 Agouron Pharmaceuticals, Inc. NON-PEPTIDE GnRH AGENTS, METHODS AND INTERMEDIATES FOR THEIR PREPARATION

Also Published As

Publication number Publication date
MXPA03011002A (en) 2004-10-28
CA2449843A1 (en) 2002-12-12
WO2002098363A2 (en) 2002-12-12
EP1401427A2 (en) 2004-03-31
JP2005501006A (en) 2005-01-13
AU2002312348A1 (en) 2002-12-16
WO2002098363A3 (en) 2003-03-20
BR0210191A (en) 2004-04-06

Similar Documents

Publication Publication Date Title
HUP0402560A3 (en) N-adamantylmethyl derivates, processes for their preparation, pharmaceutical compositions thereof and intermediates
HUP0402264A3 (en) Substituted 2-thio-3,5-dicyano-4-phenyl-6-aminopyridines process for preparing them, pharmaceutical compositions containing them and use thereof
MXPA03006775A (en) Pharmaceutical formulation.
HK1072200A1 (en) Pro-micelle pharmaceutical compositions
HUP0402225A3 (en) Macrolide-compounds, process for their preparation and pharmaceutical compositions containing them
GB0111597D0 (en) Pharmaceutical compositions
MXPA03007641A (en) Pharmaceutical formulation.
GB0118689D0 (en) Pharmaceutical formulation
PL366510A1 (en) Pharmaceutical combinations
PL366432A1 (en) Pharmaceutical formulation
HUP0400040A2 (en) Sulfonamides, process for their preparation and pharmaceutical compositions containing them
EP1401427A4 (en) Non-peptide gnrh agents, pharmaceutical compositions and methods for their uses, and processes for preparing them
AU2003233127A1 (en) Non-peptide gnrh agents, pharmaceutical compositions and methods for their use
HUP0401082A3 (en) Substituted 4-aminocyclohexanols, process for their preparation and pharmaceutical compositions containing them
GB0124523D0 (en) Pharmaceutical combination
EP1392722A4 (en) Echinocandin process
HUP0303469A3 (en) Phtalazinon-derivatives, their use and pharmaceutical compositions containing them
HUP0401644A3 (en) Aminobenzoephenones, pharmaceutical compositions containing them and use thereof
ZA200404807B (en) Imidazoquinoline derivatives.
GB0104752D0 (en) Pharmaceutical compositions
GB0129397D0 (en) Pharmaceutical combination
HUP0401038A3 (en) Piperazinylcarbonylquinolines and -isoquinolines, process for their preparation and pharmaceutical compositions containing them
GB0127720D0 (en) Pharmaceutical compositions
GB0129395D0 (en) Pharmaceutical combination
IL159561A0 (en) Eurotinones and derivatives thereof, processes for preparing them, and their use

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20040107

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

RIN1 Information on inventor provided before grant (corrected)

Inventor name: VAZIR, HARESH

Inventor name: TRUESDALE, LARRY, KENNETH

Inventor name: TOMPKINS, EILEEN, VALENZUELA

Inventor name: SHACKELFORD, SCOTT

Inventor name: RAJAPAKSE, RANJAN, JAGATH

Inventor name: PATHAK, VED, P.

Inventor name: PADERES, GENEVIEVE, D.

Inventor name: LUTHIN, DAVID, ROBERT

Inventor name: LI, HAITAO

Inventor name: KRAYNOV, EUGENIA, ANATOLIEVNA

Inventor name: HONG, YUFENG

Inventor name: GOETZEN, THOMAS

Inventor name: FENG, JUN

Inventor name: DO, QUYEN-QUYEN, THUY

Inventor name: CHRISTIE, LANCE, CHRISTOPHER

Inventor name: ANDERES, KENNA, LYNN

Inventor name: ANDERSON, MARK, B.

Inventor name: SUN, ERIC, T.

RIN1 Information on inventor provided before grant (corrected)

Inventor name: VAZIR, HARESH

Inventor name: TRUESDALE, LARRY, KENNETH

Inventor name: TOMPKINS, EILEEN, VALENZUELA

Inventor name: SHACKELFORD, SCOTT

Inventor name: RAJAPAKSE, RANJAN, JAGATH

Inventor name: PATHAK, VED, P.

Inventor name: PADERES, GENEVIEVE, D.

Inventor name: LUTHIN, DAVID, ROBERT

Inventor name: LI, HAITAO

Inventor name: KRAYNOV, EUGENIA, ANATOLIEVNA

Inventor name: HONG, YUFENG

Inventor name: GOETZEN, THOMAS

Inventor name: FENG, JUN

Inventor name: DO, QUYEN-QUYEN, THUY

Inventor name: CHRISTIE, LANCE, CHRISTOPHER

Inventor name: ANDERES, KENNA, LYNN

Inventor name: ANDERSON, MARK, B.

Inventor name: SUN, ERIC, T.

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: AGOURON PHARMACEUTICALS, INC.

A4 Supplementary search report drawn up and despatched

Effective date: 20041014

RIC1 Information provided on ipc code assigned before grant

Ipc: 7A 61P 35/00 B

Ipc: 7A 61P 15/00 B

Ipc: 7C 07D 307/68 B

Ipc: 7C 07D 405/14 B

Ipc: 7C 07D 405/12 B

Ipc: 7C 07D 405/10 B

Ipc: 7C 07D 307/58 B

Ipc: 7A 61K 31/497 B

Ipc: 7A 61K 31/443 B

Ipc: 7A 61K 31/341 A

17Q First examination report despatched

Effective date: 20070226

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20070710